TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Adagio Medical Holdings ( (ADGM) ) is now available.
On October 1, 2025, Adagio Medical Holdings announced the completion of enrollment for its FULCRUM-VT Pivotal FDA IDE study, evaluating the vCLAS™ Cryoablation System for monomorphic ventricular tachycardia. The study, which enrolled 208 patients across 20 centers in the U.S. and Canada, aims to support a pre-market approval application for the system. The vCLAS System, granted Breakthrough Device Designation by the FDA, is expected to address the needs of patients with drug-refractory ventricular tachycardia, with the PMA process anticipated to complete by the end of 2026.
The most recent analyst rating on (ADGM) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Adagio Medical Holdings stock, see the ADGM Stock Forecast page.
Spark’s Take on ADGM Stock
According to Spark, TipRanks’ AI Analyst, ADGM is a Neutral.
Adagio Medical Holdings faces significant financial challenges, with consistent losses and negative cash flows being the most impactful factors. While technical indicators suggest some positive momentum, the company’s negative P/E ratio and lack of dividend yield highlight valuation concerns. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on ADGM stock, click here.
More about Adagio Medical Holdings
Adagio Medical Holdings, Inc. is a medical device company specializing in the development and commercialization of products for treating cardiac arrhythmias. The company utilizes its proprietary Ultra-Low Temperature Cryoablation (ULTC) technology to create large, durable lesions in cardiac tissue. Adagio is currently focused on treating ventricular tachycardia with its vCLAS™ Cryoablation System, which is CE Marked in Europe and under evaluation in the U.S. through the FULCRUM-VT IDE Pivotal Study.
Average Trading Volume: 290,793
Technical Sentiment Signal: Hold
Current Market Cap: $31.07M
For detailed information about ADGM stock, go to TipRanks’ Stock Analysis page.